Updated:
RMD Partners
RMD Partners is a private equity based in Yokohama-shi, founded 2020; the Altss profile covers its classification, headquarters, registration, AUM band, and...
RMD Partners
RMD Partners is a Japan-based venture capital investment firm focused on the healthcare sector.
General information
Firm type
Private Equity
Year founded
2020
AUM
Undisclosed
Location
Region
Asia
Country
Japan
City
Yokohama-shi
Corporate office
Yokohama-shi, Japan
Sector focus
Frequently asked questions
What is the investment strategy of RMD Partners' Medical Development Support Fund?
The fund targets seed and early-stage opportunities across medical devices, carve-outs, and venture companies within the broader healthcare sector. It provides capital alongside regulatory and manufacturing partnership services, with a particular focus on helping Japanese academic and clinical inventions reach commercialization. Disclosed investments include vascular, neurological, and urological device companies.
Does RMD Partners make direct investments or fund commitments?
RMD Partners operates exclusively through its Medical Development Support Fund I, a direct investment vehicle. There is no public indication of fund-of-fund commitments; all disclosed positions represent direct equity investments into device and digital-health companies.
Which investment stages does RMD Partners typically target?
The firm explicitly targets seed and early-stage projects, citing development projects, carve-outs, and venture companies as its primary categories. This spans pre-revenue prototyping through early commercialization within the medical-device lifecycle.
Has RMD Partners realized any exits?
The firm disclosed that its portfolio company Neuroceuticals Okinawa, a medical-device development and manufacturing business, was successfully exited via M&A to Otsuka Pharmaceutical Factory. RMD Partners described it as Fund I's first realized return.
Does RMD Partners co-invest with external parties or provide syndicated deal access?
No syndication or co-investment structures are publicly disclosed. The firm's materials emphasize direct sourcing — linking overseas device seeds with Japanese manufacturing partners — but do not describe club-deal or external-LP co-investment programs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: